STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY), a biotechnology company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its ...

Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma ...

Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Indirect treatment comparison of ...

OXNARD, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that its 25mg cannabidiol (CBD) oral thin film ...

Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study. Gene expression and cytokine modulation in a first in human (FIH) study of a pan BET inhibitor ABBV-075 in solid tumors ...

VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

Dosing complete for 53 subjects in Sildenafil Oral Suspension Bioavailability Study Initiated dosing in 38 subjects in Sildenafil Oral Suspension Food-Effect Study Top-line data from both studies ...